Ryaltris FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 20, 2022.
FDA Approved: Yes (First approved January 13, 2022)
Brand name: Ryaltris
Generic name: mometasone furoate and olopatadine hydrochloride
Dosage form: Nasal Spray
Company: Glenmark Pharmaceuticals Inc.
Treatment for: Allergic Rhinitis
Ryaltris (mometasone and olopatadine) nasal spray is a corticosteroid and antihistamine combination for the treatment of seasonal allergic rhinitis (SAR) in patients 12 years of age and older.
- The corticosteroid and antihistamine ingredients in Ryaltris work together to reduce nasal inflammation associated with seasonal allergic rhinitis.
- Ryaltris is administered as two sprays in each nostril twice daily.
- Common adverse reactions include dysgeusia, epistaxis, and nasal discomfort.
Development timeline for Ryaltris
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
